论文部分内容阅读
目的观察CETD-T方案治疗复发/难治性多发性骨髓瘤的临床疗效与安全性。方法回顾性分析2007年1月至2010年1月收治的25例行CETD-T方案化疗的复发/难治性多发性骨髓瘤患者的临床资料,CETD-T方案为环磷酰胺0.2 g qd,鬼臼乙叉甙100 mg qd,吡柔比星10 mg qd,地塞米松10 mg qd,以上药物均在第1~4天连续静脉滴注维持96 h,沙利度胺100 mg~200 mg/d,每晚顿服。4周为一个疗程,至少连续接受2个疗程化疗后评定疗效。结果 25例患者中非常好的部分缓解占12.0%(3/25),部分缓解52.0%(13/25),疾病稳定24.0%(6/25),疾病进展12.0%(3/25),总有效率64.0%(16/25)。结论 CETD-T方案治疗复发/难治性多发性骨髓瘤是一种有效、能耐受的挽救性治疗方案,值得临床进一步推广使用。
Objective To observe the clinical efficacy and safety of CETD-T regimen in the treatment of relapsed / refractory multiple myeloma. Methods The clinical data of 25 patients with recurrent / refractory multiple myeloma treated with CETD-T regimen from January 2007 to January 2010 were retrospectively analyzed. The CETD-T regimen was cyclophosphamide 0.2 g qd, Etoposide 100 mg qd, pirarubicin 10 mg qd, dexamethasone 10 mg qd, the above drugs are in the first 4 days continuous intravenous infusion of 96 h, thalidomide 100 mg ~ 200 mg / d, Dayton clothing every night. 4 weeks for a course of treatment, at least two consecutive courses of chemotherapy to assess efficacy. Results The excellent partial remission rate was 12.0% (3/25) in 25 patients, 52.0% (13/25) in partial remission, 24.0% (6/25) in stable disease, 12.0% (3/25) in disease progression, Efficiency 64.0% (16/25). Conclusion CETD-T regimen is an effective and tolerable salvage therapy for relapsed / refractory multiple myeloma, which is worth further promotion in clinic.